» Articles » PMID: 31128026

L-Tetrahydropalmatine Enhances the Sensitivity of Human Ovarian Cancer Cells to Cisplatin Via MicroRNA-93/PTEN/Akt Cascade

Overview
Journal J BUON
Specialty Oncology
Date 2019 May 26
PMID 31128026
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Το evaluate the effect of L-Tetrahydropalmatine (L-THP) on the sensitivity of a cisplatin resistant ovarian cancer (OC) cell line. As miR-93 is reported to be overexpressed in OC and cisplatin resistance, we also evaluated its pathway in OC.

Methods: The levels of miR-93 were evaluated using RT-PCR and Luciferase assay was performed to confirm the target of miR-93. The extent of apoptosis was evaluated by Annexin V and propidium iodide (PI) staining, whereas Hoechst 33258 staining was done for identifying the number of apoptotic cells.

Results: The cisplatin-resistant A2780/DDP cell line showed lower survival rate compared to control when incubated with L-THP along with cisplatin. L-THP caused G0/G1 cell cycle arrest and increased the sensitivity to cisplatin. Furthermore, we found that the levels of miR-93 in cisplatin-resistant cells were highly expressed compared to parental cells. L-THP suppressed the expression of miR-93 and increased the levels of PTEN, a crucial tumor suppressor in OC. It was further observed that the cells transfected with PTEN siRNA showed increased survival compared with the control group and this phenomenon could be reversed by the AKT inhibitor Triciribine. The A2780 cells treated with PTEN siRNA showed similar survival rate to the cells with miR-93 overexpression.

Conclusion: The findings of this study suggested L-THP increased the sensitivity of ovarian cancer cells to cisplatin via modulating miR-93/PTEN/AKT pathway in A2780/DDP ovarian cancer cell line.

Citing Articles

A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment.

Xiong Z, Huang Y, Cao S, Huang X, Zhang H Front Immunol. 2025; 16:1542326.

PMID: 40013141 PMC: 11860879. DOI: 10.3389/fimmu.2025.1542326.


MicroRNA‑mediated approaches in ovarian cancer therapy: A comprehensive systematic review.

Putri H, Novianti P, Pradjatmo H, Haryana S Oncol Lett. 2024; 28(4):491.

PMID: 39185494 PMC: 11342411. DOI: 10.3892/ol.2024.14624.


Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism.

Hashem M, Khosroshahi E, Aliahmady M, Ghanei M, Rezaie Y, Jafari Y Noncoding RNA Res. 2024; 9(2):560-582.

PMID: 38515791 PMC: 10955558. DOI: 10.1016/j.ncrna.2024.01.009.


Network pharmacology and molecular docking-based analyses to predict the potential mechanism of Huangqin decoction in treating colorectal cancer.

Li Y, Tang D, Yan H, Yang B, Yang Z, Long F World J Clin Cases. 2023; 11(19):4553-4566.

PMID: 37469733 PMC: 10353508. DOI: 10.12998/wjcc.v11.i19.4553.


A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.

Saburi A, Kahrizi M, Naghsh N, Etemadi H, Ilhan A, Adili A J Ovarian Res. 2022; 15(1):81.

PMID: 35799305 PMC: 9264529. DOI: 10.1186/s13048-022-01012-1.